Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2015

01-05-2015 | Adis Drug Evaluation

Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia

Authors: Esther S. Kim, Sohita Dhillon

Published in: Drugs | Issue 7/2015

Login to get access

Abstract

Ibrutinib (Imbruvica®) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton’s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK. Oral ibrutinib is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of ibrutinib in these indications. In clinical studies, ibrutinib induced a high overall response rate in patients with relapsed/refractory MCL (phase II study). In addition, ibrutinib significantly prolonged progression-free survival and significantly improved the partial response rate and overall survival in patients with relapsed/refractory CLL (RESONATE study), including in those with del 17p, a subgroup with a poor prognosis. Ibrutinib had an acceptable tolerability profile in these studies with <10 % of patients discontinuing treatment because of adverse events. Given its efficacy and tolerability, once-daily, oral ibrutinib is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or TP53 mutation.
Literature
1.
Miranda RN, Khoury JD, Medeiros LJ. Mantle cell lymphoma. In: Miranda RN, Khoury JD, Medeiros LJ, editors. Atlas of lymph node pathology. New York: Springer; 2013. p. 229–35.CrossRef
2.
Boelens J, Lust S, Vanhoecke B, et al. Chronic lymphocytic leukemia. Anticancer Res. 2009;29(2):605–15.PubMed
3.
Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511–8.CrossRefPubMed
4.
McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159(4):405–26.CrossRefPubMed
5.
Dreyling M. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. 2014 educational book: American Society of Clinical Oncology; 2014. p. 191–8.
6.
Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–85.CrossRefPubMed
7.
8.
Sellner L, Denzinger S, Dietrich S, et al. What do we do with chronic lymphocytic leukemia with 17p deletion? Curr Hematol Malig Rep. 2013;8(1):81–90.CrossRefPubMed
9.
Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50–4.PubMed
10.
Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015;75(2):143–55.CrossRefPubMed
11.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) non-Hodgkin’s lymphomas. 2015. https://​www.​nccn.​org. Accessed 3 Feb 2015.
12.
Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83–92.CrossRefPubMed
13.
14.
15.
Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–57.CrossRefPubMed
16.
Burger JA. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9(1):44–9.CrossRefPubMed
17.
Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271–7.CrossRefPubMed
18.
Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–96.CrossRefPubMedCentralPubMed
19.
20.
21.
22.
23.
Johnson and Johnson. Application submitted to the EMA to expand the therapeutic indication for Imbruvica® (ibrutinib) to include treatment of Waldenström’s macroglobulinemia. 2014. http://​www.​investor.​jnj.​com. Accessed 9 Feb 2015.
24.
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80.CrossRefPubMedCentralPubMed
25.
Herman SEM, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286–95.CrossRefPubMed
26.
Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19+ CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412–24.CrossRefPubMedCentralPubMed
27.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.CrossRefPubMed
28.
29.
Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188–96.CrossRefPubMedCentralPubMed
30.
Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRefPubMedCentralPubMed
31.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.CrossRefPubMed
32.
Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7.CrossRefPubMedCentralPubMed
33.
Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.CrossRefPubMedCentralPubMed
34.
Martin P, Maddocks KJ, Noto K, et al. Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma [abstract no. 3047]. In: 56th ASH Annual Meeting and Exposition; 2014.
35.
Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3 K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022–35.CrossRefPubMedCentralPubMed
36.
Wang M, Rule S, Martin P, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study [abstract no. 4453]. Blood. 2014;124(21).
37.
O’Brien S, Jones JA, Coutre S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract no. 327]. In: 56th ASH Annual Meeting and Exposition; 2014.
38.
Brown JR, Hillmen P, O’Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract no. 3331]. Blood. 2014;124(21).
39.
Barrientos JC, O’Brien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE™ study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract no. 4696]. In: 56th ASH Annual Meeting and Exposition; 2014.
40.
McMullen JR, Boey EJH, Ooi JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–30.CrossRefPubMed
41.
Byrd JC, Hillmen P, James DF. Response: additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. Blood. 2015;125(10):1673.CrossRefPubMed
42.
43.
Tongbram V, Sengupta N, Gaudig M, et al. Comparative effectiveness of treatments for relapsed or refractory mantle cell lymphoma (R/R MCL), using matching adjusted indirect comparison [abstract no. PCN5]. Value Health. 2014;17(7):A614–5.CrossRef
44.
Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100(1):77–86.CrossRefPubMedCentralPubMed
45.
Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–9.CrossRefPubMedCentralPubMed
46.
Wang M, Hagemeister F, Westin JR, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial [abstract no. 627]. In: 56th ASH Annual Meeting and Exposition; 2014.
47.
Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015;11(1):51–9.CrossRefPubMed
48.
Pan F, Peng S, Sorensen S, et al. Simulation model of ibrutinib for chronic lymphocytic leukemia (CLL) with prior treatment [abstract no. PCN40]. Value Health. 2014;17(7):A620–1.CrossRef
49.
Peng S, Sorensen S, Pan F, et al. Simulation model of ibrutinib in treatment of relapsed or refractory mantle cell lymphoma (MCL) [abstract no. PCN38]. Value Health. 2014;17(7):A620.CrossRef
Metadata
Title
Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
Authors
Esther S. Kim
Sohita Dhillon
Publication date
01-05-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0380-3

Other articles of this Issue 7/2015

Drugs 7/2015 Go to the issue

Leading Article

Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges

Adis Drug Evaluation

Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Adis Drug Evaluation

Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events

Current Opinion

Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance

R&D Insight Report

Isavuconazonium: First Global Approval

Adis Drug Evaluation

Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists